imaware, the at-home testing platform for chronic illness and disease, designed by healthcare company Microdrop, announced a study utilizing its platform has been peer reviewed by Clinical Chemistry and Laboratory Medicine (CCLM). The company’s at-home blood-testing platform validates and shares its data with consumers and medical professionals. imaware offers at-home tests for celiac disease and rheumatoid arthritis, with cardiovascular health, liver disease and prostate health tests launching later this year.
imaware’s blood testing platform for patients to conduct their own screening. The company uses a microarray testing platform commonly used in research and laboratory settings that is designed for sample sizes of just 50-100 microliters of blood. By pricking their finger, people collect the blood at home in a small vial and send it to imaware for testing. Testing is conducted on imaware platforms at CLIA-certified partner laboratories located in Missouri and Texas. The results are then shared in a secure and private online portal with additional resources and access to local medical professionals.
The company designed its platform with medical advisors and has partnered with research and treatment facilities to improve chronic illness and disease screening and diagnosis. imaware patient advocacy partners include the Rheumatoid Patient Foundation and Beyond Celiac.
